My Pancreatic Cancer has recurred. How does this change my treatment choices, and are new targeted therapies using...

According to the NCCN Guidelines (2023) for Pancreatic Cancer, treatment options for recurrent disease depend on several factors:

1. Biomarker Testing: The NCCN Guidelines strongly recommend comprehensive genomic profiling to identify actionable mutations, specifically:

• BRCA1/2 mutations
• KRAS mutations
• Other DNA repair deficiencies (MSI-high, dMMR)

1. Treatment Options Based on Biomarkers: According to ASCO Guidelines (2023):

• For BRCA1/2 mutations: PARP inhibitors (like olaparib) are FDA-approved as maintenance therapy
• For MSI-high tumors: Immunotherapy with pembrolizumab is an FDA-approved option
• For KRAS G12C mutations: Sotorasib or adagrasib may be considered in clinical trials

The National Cancer Institute (NCI) outlines these standard approaches for recurrent disease:

1. Clinical trials (strongly encouraged as first consideration)
2. Systemic chemotherapy with different combinations than first-line treatment
3. Targeted therapy based on molecular testing results
4. Palliative care alongside other treatments to manage symptoms

Important recommendations:

• Discuss genetic testing with your oncologist if not already done
• Ask about clinical trial opportunities, as these may provide access to newer treatments
• Consider consulting with a major cancer center that specializes in pancreatic cancer

Always work closely with your healthcare team to determine the best treatment approach based on your specific situation, biomarker status, and previous treatments.